Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: A review of the anatolian society of medical oncology (ASMO) experience

Onkologie

Volumn 35, Issue 12, 2012, Pages 740-745

  Cetin, Bulent ^a   Benekli, Mustafa ^a   Oksuzoglu, Berna ^b   Koral, Lokman ^c   Ulas, Arife ^b   Dane, Faysal ^d   Turker, Ibrahim ^b   Kaplan, Mehmet A ^e   Koca, Dogan ^f   Boruban, Cem ^c   Yilmaz, Burcak ^g   Sevinc, Alper ^h   Berk, Veli ⁱ   Iskdogan, Abdurrahman ^e   Uncu, Dogan ^j   Harputluoglu, Hakan ^k   Coskun, Ugur ^a   Buyukberber, Suleyman ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital   (Turkey)

^c SELCUK UNIVERSITY   (Turkey)

^d MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^e DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^f DOKUZ EYLUL UNIVERSITY   (Turkey)

^g DR LUTFI KIRDAR KARTAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^h GAZIANTEP UNIVERSITY   (Turkey)

ⁱ ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^j ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^k INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

more..

Author keywords

Brain metastases; HER2; Lapatinib; Metastatic breast cancer

Indexed keywords

CAPECITABINE; LAPATINIB; TRASTUZUMAB;

ADULT; AGED; ANOREXIA; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE METASTATIC BREAST CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; REVIEW; STOMATITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PREVALENCE; QUINAZOLINES; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TURKEY;

EID: 84871057384     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000345040     Document Type: Review

References (19)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82.
2. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-7.
3. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, Howell A, Wardley AM: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-43.
4. Pestalozzi BC, Brignoli S: Trastuzumab in CSF. J Clin Oncol 2000;18:2349-51.
5. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V: Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18:23-8.
6. Bria E, Cuppone F, Fornier M, Nisticò C, Carlini P, Milella M, Sperduti I, Terzoli E, Cognetti F, Giannarelli D: Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A metaanalysis of the randomized trials. Breast Cancer Res Treat 2008;109:231-9.
7. Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, Eisenhauer E: Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol 2006;17:952-6.
8. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin G, Hortobagyi GN, Buchholz T: Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006;107:1348-54.
9. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
10. Polli J, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, John-Williams LS, Koch KM, Serabjit-Singh CJ: The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2- (methylsulfonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metable Dispos 2008;36:695-701.
11. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533-43.
12. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26:1993-9.
13. Boccardo F, Kaufman B, Baselga J, Dieras J, Link J, Casey MA, Fittipaldo A, Oliva C, Zembryki D, Rubin SD: Evaluation of lapatinib plus capecitabine in patients with brain metastases from HER2+ breast cancer enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilization (ATU). J Clin Oncol 2008;26(suppl):abstr 1094.
14. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-9.
15. Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, Bhatti R, Shehata M, Nouras H, Camburn T, Johnston SRD: Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases -the UK experience. Br J Cancer 2010;102:995-1002.
16. Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, Crino L, Papoldo P, Mottolese M, Cognetti F, Fabi A, Gori S: Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011;22:625-30.
17. Bachelot TD, Romieu, G, Campone, M, Dieras V, Cropet C, Roche HH, Jimenez M, Le Rhun E, Pierga J, Gonçalves A, Leheurteur M, Domont J, Gutierrez M,Cure H,Ferrero C, Labbe C: LANDSCAPE: an FNCLCC phase II study with lapatinib and capecitabine in patients with brain metastases from HER2-positive metastatic breast cancer before whole brain radiotherapy. J Clin Oncol 2011; 29:47s(abstr 509).
18. Palmieri D, Gril BM, Herring J, et al.: Lapatinib prevents the metastatic colonization of EGFR+ and Her-2+ breast cancer cells in the brain. Breast Cancer Res Treat 2007;106(suppl 1):S30(abstr 210).
19. Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI: Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR-and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004;58:344-52.